This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seattle Genetics' Adcetris Label Expands in EU for Lymphoma
by Zacks Equity Research
Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.
Myovant Eyes Relugolix Approval for Advanced Prostate Cancer
by Zacks Equity Research
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix as a treatment for advanced prostate cancer.
These 10 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Myovant Up on Successful Completion of Prostate Cancer Study
by Zacks Equity Research
Myovant's (MYOV) phase III study evaluating lead pipeline candidate, relugolix, in patients with advanced prostate cancer meets primary endpoint.
Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3
by Zacks Equity Research
Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.
4 Biotech Stocks That Could Keep Beating Wall Street
by Zacks Equity Research
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark
by Zacks Equity Research
Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.
Easy Investing Secrets to an Early Retirement - October 11, 2019
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Signs That Your Trading Will Ruin Your Retirement - October 09, 2019
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Karyopharm Signs $150M Royalty Agreement to Support Xpovio
by Zacks Equity Research
Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.
Is Takeda (TAK) a Profitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Takeda (TAK) stock is a good choice for value-oriented investors right now from multiple angles.
How Do Earnings Impact The Stock Market?
by Panel Of Zacks Experts
Q2 Earnings Season is in full swing and Sheraz Mian joins the show to discuss everything you need to know!
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.
J&J Submits BLA for Subcutaneous Formulation of Darzalex
by Zacks Equity Research
Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma
by Zacks Equity Research
Johnson & Johnson's (JNJ) label expansion application, seeking approval for Darzalex+Revlimid to treat transplant ineligible newly diagnosed patients with multiple myeloma, receives FDA approval.
AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study
by Zacks Equity Research
AbbVie (ABBV) receives encouraging news as FDA lifts partial clinical hold on a late-stage study evaluating Venclexta in relapsed/refractory multiple myeloma.
Verastem Up on Positive Data From Early-Stage Copiktra Study
by Zacks Equity Research
Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.
Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.
What's in the Cards for Sunesis (SNSS) This Earnings Season?
by Zacks Equity Research
Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
Top Ranked Income Stocks to Buy for April 25th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 25th
Kamada to Begin Phase III Study for Inhaled AAT Product in 2H
by Zacks Equity Research
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.